Jaguar Animal Health Inc (NASDAQ:JAGX) Make Changes To Chair Scientific Advisory Board


Jaguar Animal Health Inc (NASDAQ:JAGX) and Napo Pharmaceuticals, Inc. reported the appointment of Dr. Pravin Chaturvedi, as Chair of the combined firm’s Scientific Advisory Board, after the projected close of the planned merger of the two companies.

Dr. Chaturvedi has worked as Chair of Napo Pharmaceuticals’ Scientific Advisory Board since March 2017. He is responsible for offering guidance on tactics, oversight and strategy pertaining advancing the commercialization and development of the firms’ drug pipelines, comprising, but not confined to, SB-300 and Mytesi®.

The details

From 2006 to 2013, Dr. Chaturvedi worked as Napo’s CSO and has been a scientific adviser to the firm since 2014. His record of successful development comprises participating in and/or directing development efforts for as many as seven drugs, including Mytesi® product, which is permitted by the U.S. FDA for the indicative relief of noninfectious diarrhea in people with HIV/AIDS on antiretroviral treatment.

For this indication, Dr. Chaturvedi directed the key opinion leader measures that contributed to the use of adaptive clinical study design for the Mytesi® pivotal study and its approval by the U.S. FDA. As reported on March 31, 2017, Jaguar and Napo finalized a definitive merger deal.

The two companies are in the process of assessing probable follow-on indications for Mytesi® under the expected combination of the product pipelines of these firms. Dr. Chaturvedi is chairing the study of Mytesi® for probable follow-on indications, which comprise irritable bowel syndrome, chemotherapy-induced diarrhea, for which POC data is already in hand, diarrhea and inflammatory bowel diseases ensuing from hospital-acquired infections like Clostridium difficile.

Napo recently organized a Scientific Advisory Board conference with expert gastroenterologists, who offered advice on trial populations and designs in IBD and IBS. Douglas Drossman, MD noted that the safety profile of crofelemer comprises a benefit that differentiates it from other gastrointestinal products.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.